IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced the granting of non-qualified stock options to a newly hired employee. The Compensation Committee approved options to purchase 34,000 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan. These options, granted on August 29, 2024, have an exercise price of $39.17 per share, equal to the closing price of IDEAYA's stock on the grant date. The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences (NASDAQ: IDYA), un'azienda di oncologia di medicina di precisione, ha annunciato la concessione di opzioni su azioni non qualificate a un nuovo dipendente. Il Comitato per la Compensazione ha approvato opzioni per l'acquisto di 34.000 azioni ordinarie nell'ambito del piano di incentivi per l'impiego del 2023 dell'azienda. Queste opzioni, concesse il 29 agosto 2024, hanno un prezzo di esercizio di $39,17 per azione, corrispondente al prezzo di chiusura delle azioni di IDEAYA nella data di concessione. Le opzioni hanno un termine di 10 anni e si matureranno in quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura mensilmente nei tre anni successivi, a condizione di continuare l'impiego.
IDEAYA Biosciences (NASDAQ: IDYA), una empresa de oncología de medicina de precisión, ha anunciado la concesión de opciones sobre acciones no calificadas a un nuevo empleado. El Comité de Compensación aprobó opciones para comprar 34,000 acciones ordinarias bajo el Plan de Incentivos por Empleo de 2023 de la empresa. Estas opciones, concedidas el 29 de agosto de 2024, tienen un precio de ejercicio de $39.17 por acción, igual al precio de cierre de las acciones de IDEAYA en la fecha de concesión. Las opciones tienen un plazo de 10 años y se consolidarán en cuatro años, con el 25% consolidándose después del primer año y el 75% restante consolidándose mensualmente durante los tres años siguientes, sujeto a la continuidad del empleo.
IDEAYA 바이오사이언스(NASDAQ: IDYA)는 정밀 의학 종양학 회사로, 신입 사원에게 비자격 주식 옵션을 부여한다고 발표했습니다. 보상위원회는 회사의 2023년 고용 유인 인센티브 상 수여 계획에 따라 34,000주의 보통주를 매입할 수 있는 옵션을 승인했습니다. 이 옵션은 2024년 8월 29일에 부여되었으며, 주당 $39.17의 행사 가격을 가집니다. 이는 부여일의 IDEAYA 주식 종가와 같습니다. 이 옵션은 10년의 기간을 가지며 4년에 걸쳐 배정됩니다, 첫 해에 25%가 배정되고 남은 75%는 향후 3년 동안 매달 배정됩니다. 이는 계속 고용될 경우에 해당됩니다.
IDEAYA Biosciences (NASDAQ: IDYA), une entreprise d'oncologie spécialisée dans la médecine de précision, a annoncé l'octroi d'options d'achat d'actions non qualifiées à un nouvel employé. Le Comité de Rémunération a approuvé des options pour acheter 34 000 actions ordinaires dans le cadre du Plan d'Incitation à l'Emploi 2023 de l'entreprise. Ces options, accordées le 29 août 2024, ont un prix d'exercice de 39,17 $ par action, égal au prix de clôture des actions IDEAYA à la date d'octroi. Les options ont un terme de 10 ans et seront acquises sur quatre ans, avec 25 % acquises après la première année et les 75 % restants acquises mensuellement au cours des trois années suivantes, sous réserve d'une poursuite d'emploi.
IDEAYA Biosciences (NASDAQ: IDYA), ein Unternehmen der Onkologie mit präziser Medizin, hat die Gewährung von nicht qualifizierten Aktienoptions an einen neu eingestellten Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen zum Kauf von 34.000 Aktien des Unternehmens im Rahmen des 2023 Employment Inducement Incentive Award Plans. Diese Optionen, die am 29. August 2024 gewährt wurden, haben einen Ausübungspreis von $39,17 pro Aktie, der dem Schlusskurs der IDEAYA-Aktie am Gewährungstag entspricht. Die Optionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre fällig, wobei 25% nach dem ersten Jahr und die verbleibenden 75% monatlich über die folgenden drei Jahre fällig sind, vorbehaltlich einer fortgesetzten Beschäftigung.
- Granting of stock options may help attract and retain talented employees
- The exercise price is set at market value, aligning employee interests with shareholders
- Potential dilution of existing shareholders' equity due to new stock options
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302234611.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
How many stock options did IDEAYA Biosciences (IDYA) grant on August 29, 2024?
What is the exercise price of the stock options granted by IDEAYA Biosciences (IDYA)?
What is the vesting schedule for the stock options granted by IDEAYA Biosciences (IDYA)?
Under which plan were the stock options granted by IDEAYA Biosciences (IDYA)?
